Mangoceuticals, Inc. (MGRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mangoceuticals, Inc., a Texas corporation listed on the Nasdaq Capital Market, on September 12, 2025. The report covers events occurring on September 9, 2025, specifically regarding the approval of equity grants to executive officers and board members under the Second Amended and Restated Mangoceuticals, Inc. 2022 Equity Plan.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the valuation of equity grants:
- Stock Price: $2.30 per share (closing price on September 9, 2025).
- Option Exercise Price: $2.30 per share.
Material Changes and Equity Grants
Effective September 9, 2025, the Board of Directors approved the following grants:
- Jacob D. Cohen (CEO):
- 500,000 shares of common stock (fully vested immediately).
- Options to purchase 2,000,000 shares of common stock.
- Eugene M. Johnston (CFO): 100,000 shares of common stock (fully vested immediately).
- Kenny Myers (Director): 100,000 shares of common stock (fully vested immediately).
- Alex Hamilton (Director): 100,000 shares of common stock (fully vested immediately).
- Lorraine D'Alessio (Director): 100,000 shares of common stock (fully vested immediately).
Option Terms (CEO Only): The 2,000,000 options have a 10-year term. Vesting is structured as 500,000 shares upon grant, with the remaining 1,500,000 vesting in three equal tranches of 500,000 on the 6th, 12th, and 18th-month anniversaries, subject to continued service. Full acceleration occurs upon termination without cause, termination for good reason, or a change of control.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of specific risks or contingencies beyond the standard terms of the equity plan. The grants are described as compensation for services rendered during 2025.
Investor Verification Checklist
- Verify the total number of shares authorized under the 2022 Equity Plan to assess remaining capacity for future grants.
- Confirm the dilution impact of the 900,000 newly issued shares and the potential dilution from 2,000,000 options.
- Review the attached Option Agreement (Exhibit 10.2) for specific performance conditions or clawback provisions not detailed in the summary.
- Check recent stock price trends relative to the $2.30 exercise price to evaluate the intrinsic value of the CEO's options.